Covariate effects for PFS
EVENT
Table Covariate effects in the final model of progression-free survival model. Reference is a male patient with nivolumab clearance of 0.009 L/h, baseline albumin of 41 g/L, and CAVG0T, the predicted average cabozantinib concentration from time zero to the event or censoring, of 558 ng/mL. Continuous covariates are tested at the 5th and 95th percentile values. Hazard ratio (HR) estimate along with 90% confidence interval (CI) represents the change in log(HR) per unit change in the continuous variable, or the difference in log(HR) between comparator/reference variables (categorical), assuming all other covariates are constant